Oramed Pharmaceuticals (ORMP) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $149.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORMP | RNA |
|---|---|---|
| Share price | $3.57 | $6.92 |
| Market cap | $155.24M | $149.27M |
| 1-day change | -3.25% | -0.86% |
| YTD return | +25.26% | — |
| 1-year return | +38.37% | — |
| 5-year return | -82.34% | — |
| P/E ratio (TTM) | 1.05 | — |
| EPS (TTM) | $3.41 | $-5.22 |
| Dividend yield | 7.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.00M | — |
| Net income (latest FY) | $64.05M | — |
| Gross margin | 0.65% | — |
| Operating margin | -754.40% | — |
| Net margin | 3202.50% | — |
| 52-week high | $5.47 | $16.77 |
| 52-week low | $2.52 | $6.36 |
| Distance from 52-week high | -34.73% | -58.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +96.08% | +217.92% |
| Average volume | 173.38K | 297.20K |
| Shares outstanding | 43.49M | 21.57M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
ORMP vs RNA FAQ
Which is bigger, Oramed Pharmaceuticals or Atrium Therapeutics?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $149.27M for Atrium Therapeutics (RNA).
Which pays a higher dividend, Oramed Pharmaceuticals or Atrium Therapeutics?
Oramed Pharmaceuticals pays a dividend yielding 7.00%, while Atrium Therapeutics does not currently pay a regular dividend.
Are Oramed Pharmaceuticals and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.